Sex-Specific Genetic Architecture and Comorbidities of Alcohol Use Behaviors

Running title: "Sex-Specific Alcohol Genetics and Comorbidities"

Laura Vilar-Ribó, PhD.[1] Mariela V Jennings, BS.[1] Aisha Sallah, BS.,[2] Maria Niarchou, PhD.[8]

Zeal Jinwala, BS.,[3,4,5] Hayley HA Thorpe, PhD.[6] Sevim B Bianchi, BS.[1] John Meredith, BS.,[1]

Kyra Feuer, PhD.,[3] Lydia Rader, PhD.,[7] Natasia Courchesne-Krak, PhD.,[1] Jared Balbona,

PhD.,[9, 10] 23andMe Research Institute.[11] Sarah L Elson, PhD.,[11] Pierre Fontanillas, PhD.,[11]

Emma C Johnson, PhD.,[12] Lea K Davis, PhD.,[13,14,15] Alexander S Hatoum, PhD.,[16] Travis T

Mallard, PhD.,[17,18] Daniel E Gustavson, PhD.,[7,19] Hang Zhou, PhD.,[20,21] Abraham A Palmer,

PhD.,[1,22] Jeanne E Savage, PhD.,[23] Rachel L Kember, PhD.,[3,4] Sandra Sanchez-Roige,

PhD.,[1,14,22]*

[1] Department of Psychiatry, University of California San Diego, La Jolla CA, USA

[2] Genetics and Epigenetics Graduate Group, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA, USA

[3] Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States

[4] Crescenz VA Medical Center, Philadelphia, PA 19104, United States

[5] Division of Biology & Biomedical Sciences, Washington University in Saint Louis

[6] Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, Western
University, London, ON, Canada

[7] Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO

[8] Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center,
Nashville, TN, USA

[9] Virginia Institute for Psychiatric and Behavioral Genetics, Richmond, VA, USA

[10] Department of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond,
VA, USA

[11] 23andMe, Research Institute, Palo Alto, CA, USA

28   [12] Department of Psychiatry, Washington University School of Medicine, St Louis, MO

29   [13] Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN,
30   USA

31   [14] Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

32   [15] Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center,
33   Nashville, TN, USA

34   [16] Washington University School of Medicine, Department of Psychiatry, St. Louis MO

35   [17] Center for Precision Psychiatry, Department of Psychiatry, Massachusetts General Hospital,
36   Boston, MA, USA

37   [18] Department of Psychiatry, Harvard Medical School, Boston, MA, USA

38   [19] Department of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO,
39   United States

40   [20] Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA

41   [21] Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA

42   [22] Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA

43   [23] Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research,
44   Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands
45
Corresponding Author: Sandra Sanchez-Roige, PhD
Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA,
USA, 92093; Phone: +1-619-874-1426; Email: sanchezroige@ucsd.edu

Key words: Sex-stratified genome-wide association study; alcohol use disorder; Alcohol
consumption; Addiction genetics; Sex-stratified Phenome-wide association study; Externalizing
and internalizing comorbidity.

ABSTRACT

Background: Sex differences in alcohol use behaviors are well-established: males typically engage in heavier and more frequent drinking and exhibit more externalizing behaviors (e.g., other substance use), while females often transition to dependence more rapidly and present more internalizing psychopathology (e.g., depression). The biological mechanisms underpinning these differences are relatively unknown.

Methods: In this study, we investigated the sex-differentiated genetic architecture of 11 alcohol use phenotypes pertaining to frequency, quantity and problematic use by leveraging sex-stratified genome-wide association studies (Ns 40,335 to 613,148). Specifically, we compared SNP-based heritability (h^2_{SNP}) estimates, individual genetic locus effects, genetic correlations (r_g) across alcohol phenotypes and with comorbid traits from independent GWAS, and polygenic score (**PGS**) associations with medical outcomes from clinical populations.

Results: h^2_{SNP} was broadly similar between sexes, except for higher estimates in males for *beer quantity* and *problematic alcohol use* (**PAU**). We identified four sex-differentiated top loci ($p_{sex\text{-}diff}$ < 5 x 10^{-8}), including a female-specific association in *IZUMO1* for *drinking frequency* and *quantity*, and three male-specific associations in *ADH1B*, *KLB* and *FTO* for *beer quantity* and/or *PAU*. Between-sex genetic correlations ranged from 0.68±0.07 to 0.89±0.04, these estimates were lowest for quantity measures and varied by beverage type, indicating partially distinct polygenic architecture. In males, we identified stronger positive genetic correlations with several externalizing traits (e.g., general addiction) compared to females. In females, we identified a specific positive genetic correlation with a single internalizing trait, self-harm. PGS analyses revealed sex-specific medical associations (e.g., bone/musculoskeletal conditions in females; hepatic/respiratory/infectious sequelae in males) that were obscured in sex-combined analyses; however, sex-specific PGS did not outperform combined-sex PGS for predicting alcohol use disorder diagnosis.

Conclusions: Sex-aware analyses of alcohol use behaviors can improve our understanding of the genetic etiology of alcohol use and related health outcomes, and future studies should consider cultural variation (e.g., drinking attitudes, social norms) in the relationship between behavior and genetics.

INTRODUCTION

Alcohol use disorder (**AUD**) afflicts over 15 million Americans, costs the US economy $249 billion annually, and kills more than 3 million people a year globally[1,2]. AUD develops through a dynamic process, which begins with the initiation of use, continues with the escalation to hazardous drinking, and can lead to compulsive, harmful use that persists despite negative consequences[3]. AUD often manifests alongside other psychiatric and medical comorbidities, such as liver disease, cardiovascular conditions, pancreatitis, and metabolic disorders[4–6].

Although males are more likely to be diagnosed with AUD than females, this gap is closing in western countries[7]. The trajectory of AUD development, however, is sex specific. While males are more prone to heavy drinking, females often transition to dependence more quickly[8], show more susceptibility to cravings[9] and relapse[10], and experience aggravated adverse events to AUD medications[11]. Alcohol-related psychiatric comorbidities are also sex-specific. For example, males are more likely to exhibit externalizing disorders (e.g., other substance use disorders [**SUD**]), whereas females are more likely to manifest internalizing psychopathology (e.g., depression;[12,13]. Even at lower consumption levels[14,15] females are disproportionately affected by medical comorbidities (e.g., liver disease, neurological damage, cardiovascular conditions)[16–19]. Many factors, both biological (e.g., hormones, body composition, metabolism) and environmental (e.g., cultural norms, social roles, beverage preferences), can shape these trajectories differently across sexes[7,20].

Twin studies show that sex-specific AUD trajectories and comorbidities arise in part from genetic factors[7,17,21], with some studies reporting slightly lower heritability estimates in females (e.g., 40-45% in females, 50-52% in males). A recent genome-wide association study (**GWAS**) identified potential sex-differentiated genetic variants (i.e., variants that are significantly different in the magnitude or direction of effect between sexes) associated with problematic alcohol use (**PAU**)[22]. However, this study included substantially fewer females than males ($N_{females}$ = 143,198 vs. N_{males} = 496,548), resulting in power imbalances between sexes. In addition, the genetic architecture of AUD is not identical to that of alcohol consumption[3,23–25] and the sex-differentiated genetic architecture across the broader spectrum of alcohol use behaviors has yet to be explored. Identifying sex-differentiated genes and biological pathways underlying alcohol use behaviors and comorbidities may enable personalized AUD treatments and prevention strategies that are tailored to sex and accommodate heterogeneous profiles.

In the present study, we performed a systematic genomic characterization of sex differences across the spectrum of alcohol use behaviors. We leveraged data from previously

published sex-stratified GWAS including PAU[22], 9 alcohol use behavior phenotypes from UK

Biobank[26] ($N_{females}$ = 67,076 - 191,917 vs. N_{males} = 53,332 - 168,772), and a new, unpublished sex-

stratified GWAS of Alcohol Use Disorder Identification Test (**AUDIT**) total scores from 23andMe

Research Institute ($N_{females}$ = 72,444 vs. N_{males} = 40,335). We examined the sex-differentiated

genetic architecture of these phenotypes, across both *quantitative* effects (i.e., the magnitude of

genetic influence by sex) and *qualitative* effects (i.e., specific genetic variants). Specifically, we

compared SNP-based heritability (***h²**_SNP_*) estimates, individual genetic locus effects, genetic

correlations (***r_g***) across alcohol phenotypes and with comorbid traits from independent GWAS,

and PGS associations with medical outcomes from clinical populations. We had three specific

hypotheses. First, that sex-differentiated genetic effects would be more pronounced in alcohol

phenotypes influenced by body size (e.g., body mass index [**BMI**]) and metabolic processes, such

as drinking quantity, given that these traits tend to differ between females and males[27]. We

expected that these differences would be less evident for phenotypes that reflect behavioral or

psychiatric components of AUD, such as drinking frequency or problematic alcohol use. Second,

that externalizing comorbidities would be more strongly associated in males, whereas

internalizing comorbidities would show stronger associations in females based on epidemiologic

and twin evidence of sex-differentiated comorbidity profiles[28,29]. Third, although we anticipated

that sex-combined PGS, which are trained on pooled datasets with larger sample sizes, would

outperform sex-specific PGS in predicting AUD diagnosis[30–33], we hypothesized that sex-specific

PGS would uncover associations with sex-specific comorbidities that may be masked in sex-

agnostic analyses.

METHODS

Sex-stratified GWAS

We included sex-stratified GWAS summary statistics for 11 alcohol use phenotypes

across three categories: frequency (*drinking frequency, drinking with meals* and *decreased*

drinking), quantity (*drinking quantity, beer quantity, spirit quantity, red wine quantity* and *white*

wine quantity) and problematic use (*binge drinking, AUDIT total score* and *PAU*) (**Table 1**).

Phenotypes were selected based on prior evidence of differences in between-sex genetic

correlation (r_g < 0.9)[26]. We additionally excluded phenotypes with non-significant or low h^2_{SNP} in

the sex-combined sample (h^2_{SNP} < 0.03 and/or Z-score < 10) to ensure reliable results[34]. The full

list of phenotypes excluded based on these criteria is shown in the **Supplemental Material** and

in **Figure S1**. All GWAS were restricted to individuals of genetically inferred European ancestry

based on reference populations due to the unavailability of adequately powered sex-stratified

GWAS in other ancestral populations[35,36]. Methods used to perform the sex-stratified AUDIT total

score GWAS can be found in the **Supplemental Material**. Methods used to perform the sex-

stratified GWAS on the remaining datasets can be found in the original publications[22,26].

Table 1. Summary of the 11 alcohol use phenotypes included in the study, spanning measures of frequency, quantity, and problematic use. Results are presented for sex-combined as well as female- and male-specific GWAS datasets. For continuous phenotypes, mean values and standard errors are reported, while for binary phenotypes the proportion of cases is provided.

Categories	Phenotype	Description	Cohort	Sample	N	% Females	mean (sd)	% cases	Reference
Frequency	Drinking frequency	Typical number of drinking days per month (Continuous)	UK Biobank	Combined	360,728	53.2	10.13 (7.04)	-	Savage et al., 2024
				Females	191,917	-	9.04 (6.99)	-	
				Males	168,772	-	11.38 (6.87)	-	
	Drinking with meals	Typically consume alcohol with meals vs. not (Binary)	UK Biobank	Combined	197,760	52.13	-	68.50%	Savage et al., 2024
				Females	103,090	-	-	77.64%	
				Males	94,647	-	-	58.52%	
	Decreased drinking	Drinking has decreased over the past 10 years (Binary)	UK Biobank	Combined	303,960	51.37	-	53.80%	Savage et al., 2024
				Females	156,140	-	-	51.15%	
				Males	147,789	-	-	56.64%	
Quantity	Drinking quantity	Typical gm ethanol consumed per month (Continuous)	UK Biobank	Combined	333,063	51.9	2.45 (1.06)	-	Savage et al., 2024
				Females	172,985	-	2.12 (1.01)	-	
				Males	160,040	-	2.81 (1.00)	-	
	Beer quantity	Typical quantity of beer consumed per month (Continuous)	UK Biobank	Combined	303,569	50.6	1.34 (1.48)	-	Savage et al., 2024
				Females	153,606	-	0.47 (0.92)	-	
				Males	149,932	-	2.23 (1.41)	-	
	Spirit quantity	Typical quantity of spirits	UK Biobank	Combined	302,588	50.60	0.89 (1.31)	-	Savage et al., 2024
				Females	153,100	-	0.79 (1.22)	-	

		consumed per month (Continuous)		**Males**	149,457	-	1.00 (1.38)	-	
	Red wine quantity	Typical quantity of red wine consumed per month (Continuous)	UK Biobank	**Combined**	303,004	50.63	1.79 (1.51)	-	Savage et al., 2024
				Females	153,399	-	1.65 (1.45)	-	
				Males	149,574	-	1.92 (1.55)	-	
	White wine quantity	Typical quantity of white wine consumed per month (Continuous)	UK Biobank	**Combined**	302,776	50.61	1.39 (1.42)	-	Savage et al., 2024
				Females	153,236	-	1.63 (1.43)	-	
				Males	149,574	-	1.13 (1.37)	-	
Problematic use	**Binge drinking**	Typical number of binge drinking days per month (Continuous)	UK Biobank	**Combined**	120,422	55.7	0.46 (0.71)	-	Savage et al., 2024
				Females	67,076	-	0.32 (0.59)	-	
				Males	53,332	-	0.64 (0.80)	-	
	AUDIT total score	Sum of items 1–10 to assess alcohol use over the past year (Continuous)	23andMe	**Combined**	112,779	64.24	3.82 (3.76)	-	Current study
				Females	72,444	-	4.54 (4.06)	-	
				Males	40,335	-	3.42 (3.52)	-	
	Problematic alcohol use	AUD + AUDIT-P (Binary and continuous)	MVP + FinnGen + UKB + PGC + QIMR + iPSYCH + YP3	**Combined**	903,147	32.11	0.76 (2.02)	12.50%	Zhou et al., 2023
				Females	143,198	-	0.57 (1.79)	21.20%	
				Males	496,548	-	1.01 (2.25)	18.6%	

Note: AUD = alcohol use disorder. AUDIT = Alcohol use disorder identification test

Note: Phenotype inclusion was $h^2_{SNP} > 0.3$ and between sex $r_g < 0.9$. AUDIT-P was excluded because its a subset of the PAU sample

Sex-specific heritability and genetic correlation analyses

We calculated h^2_{SNP} using linkage disequilibrium score regression (**LDSC**)[37]. SNPs were
mapped to HapMap3 data using pre-computed linkage disequilibrium scores included with the
software ("eur_w_ld_chr"). For binary phenotypes, we estimated h^2_{SNP} on the liability scale using
population prevalences (**Table S1**). We also used LDSC to estimate genetic correlations (r_g)
among alcohol use phenotypes, both between and within sexes, as well as with 71 complex traits
from published sex-combined GWAS related to alcohol use and AUD based on prior literature,
including other substance use, externalizing, internalizing, cognitive, sociodemographic and
anthropometric traits[5,38–40]. For each alcohol phenotype, we applied a 5% FDR threshold to
account for multiple testing.

Sex-differentiated genetic effects

To identify loci with sex-differentiated genetic effects, we compared SNP effect sizes
derived from sex-stratified GWAS of each alcohol use phenotype by calculating Z-scores and
corresponding *p*-values across the genome. We focused on loci with genome-wide significant
sex-differentiated effects ($p_{sex-diff} < 5 \times 10^{-8}$) and that reached genome-wide significance in one
sex but not in the other. While the most direct approach to identify SNPs with sex-differentiated
effects is through genotype-by-sex interaction analyses, it requires access to individual-level data.
A widely used alternative, which is statistically similar when covariate interactions and variance
differences are equivalent in the two sexes, is to compare effect sizes from sex-stratified GWAS
using a Z-score-based difference test[41].

Polygenic score phenome-wide association analyses (PheWAS)

To investigate sex-specific medical associations, we conducted PheWAS of both sex-
specific and sex-combined alcohol use PGS against thousands of medical outcomes in two
clinical cohorts (described below). PheWAS were meta-analyzed across sites using fixed effects
in METAL v0.99.6.1[42]. We examined the association between sex-specific PGS in sex-stratified
samples and sex-combined PGS in the total sample for each alcohol use phenotype. Medical
outcomes were derived by mapping ICD-9 and ICD-10 codes to 1,817 "phecodes", as described
and validated by the Phecode Map 1.2b[43]. Phecodes use a standardized vocabulary and denote
diseases, traits, or symptoms (http://phewascatalog.org). We excluded phecodes with less than
100 cases and phecodes that were sex-specific (i.e., unique to one sex, such as endometriosis).

Vanderbilt University Medical Center biobank (BioVU). The BioVU cohort was composed

of 66,914 unrelated individuals (females = 37,239; males = 29,675) who provided electronic health

records (**EHR**) to the Vanderbilt University Medical Center (VUMC; IRB #160302, #172020,

#190418)[44]. Genotyping used the Illumina MEGA_ex platform, with imputation via the Michigan

Imputation Server[45]. SNPs with imputation quality ($R^2 > 0.3$) were converted to hard genotype

calls. We applied an IBD filter of 0.2 to exclude cryptic relatedness. Genetic ancestral groups

were determined based on principal component analysis (**PCA**) and comparison to known

ancestries in the 1000 Genomes Project Phase 3[46] reference panel; we restricted the analyses to

individuals most genetically similar to European reference populations. We also applied a minor

allele frequency (**MAF**) filter of 0.05. Details on genotyping and quality control are available for

VUMC[47].

Penn Medicine BioBank (PMBB). PMBB is an EHR-linked biobank at the University of

Pennsylvania (Penn Medicine) with 44,297 participants. PMBB samples were genotyped by the

GSA genotyping array. Quality control removed SNPs with marker call rate <95% and sample call

rate <90%, and individuals with sex discrepancies. Genotype phasing and imputation was

performed on the TOPMed Imputation server[45]. The phasing was done using EAGLE (v2.4.1)[48]

and imputation was performed using MINIMAC software[45]. IBD analysis was used to check for

relatedness among imputed samples using PLINK v.1.9[49]. We randomly removed one individual

from each pair of related individuals (pihat <0.25). SNPs with an INFO score <0.3, MAF <0.01, a

genotype call rate <0.95 or an HWE p<1.00E-6 were removed and restricted the analyses to

individuals most genetically similar to European reference populations (N = 29,160; females =

12,998; males = 16,162). To estimate genetic ancestry, principal components (**PC**) were

calculated based on common SNPs between PMBB and the 1000 Genomes Project phase 3[46]

using the smartpca module of the Eigensoft package[50]. Participants were assigned to an ancestry

based on the distance of 10 PCs from the 1000 Genomes reference populations.

We computed PGS using PRS-Continuous shrinkage software (**PRS-CS**)[51] using default

"auto" settings to estimate shrinkage parameters and random seed fixed for reproducibility.

Logistic models were fitted for each of the phecodes using the PheWAS v0.12 R package[43]

adjusting for sex when appropriate, median age of longitudinal EHR, and the first 10 PCs of

genotype. To quantify the variance in AUD explained by each PGS, the adjusted partial

Nagelkerke pseudo-R^2 was computed using the rsq.partial() function from the *rsq* R package

v.2.7[52]. The weighted average Nagelkerke R^2 across sites was calculated with the formula

Nagelkerke-R^2_{WA} = $\sum w_i * R_i^2 / \sum w_i$. For each alcohol phenotype, we used a 5% false discovery rate

(**FDR**) threshold to correct for multiple testing within each phenotype.

Statistical tests to estimate sex differences

Sex differences were quantified following best practices[41] by computing a Z-score of the

test statistics: $Z = (X_F - X_M)/sqrt(se_F^2 + se_M^2)$, where X represents h^2_{SNP}, SNP effect sizes, r_g or

odds ratio (OR) and se represents the standard error, for females and males, respectively. This

test is the standard approach for assessing differences between independent parameters with

known standard errors and under the assumption that the estimates are normally distributed, a

condition typically met in GWAS due to large sample sizes[53]. A two-tailed test was performed to

obtain the associated $p_{sex\text{-}diff}$ value. We applied a 5% FDR threshold to account for multiple testing

for all tests, except for the sex-differentiated effect sizes, where genome-wide significance was

defined as $p_{sex\text{-}diff} < 5 \times 10^{-8}$.

RESULTS

SNP-based heritability

All 11 alcohol use phenotypes had significant h^2_{SNP} estimates, ranging from 0.031 ± 0.003

to 0.128 ± 0.007 (**Figure S2**; **Table S2**). Only two phenotypes showed statistically significantly

greater h^2_{SNP} estimates in males compared to females: *beer quantity* (male h^2_{SNP} = 0.097 ± 0.006,

female h^2_{SNP} = 0.031 ± 0.003, $p_{sex\text{-}diff}$ = 3.83e-23*)* and *PAU* (male h^2_{SNP} = 0.083 ± 0.004, female

h^2_{SNP} = 0.045 ± 0.005, $p_{sex\text{-}diff}$ = 3.94e-09). The remaining alcohol use phenotypes showed similar

h^2_{SNP} estimates across sexes (**Table S2**).

Sex-differentiated genetic effects

Figure 1A shows the number of independent genome-wide significant loci in females

(range = 1-23) and males (range = 0-40). While the magnitude of effect across variants was

largely similar across sexes (**Figure S3 and S4**), we identified four independent loci with

significant sex-differentiated effects ($p_{sex\text{-}diff} < 5 \times 10^{-8}$) that reached genome-wide significance in

one sex but not in the other across four alcohol traits (**Figure 1B**, **Table S3**). One locus (lead SNP

rs838147 in *IZUMO1*) showed female-specific effects for both *drinking frequency* (OR$_F$ = 0.87

[0.83, 0.91]) and *drinking quantity* (OR$_F$ = 0.98 [0.97, 0.99]; **Figure S5A-B**). Two loci (lead SNPs

rs1229984 in *ADH1B*, rs28712821 in *KLB)* showed male-specific effects for *beer quantity* (OR$_M$

= 0.81 [0.77, 0.84] and OR$_M$ = 0.96 [0.95, 0.97], respectively) and one locus (lead SNP rs1421085

in *FTO*) showed male-specific effects for *PAU* (OR_M = 1.02 [1.02, 1.03]; **Figure S5C-E**). Two of

these loci (rs838147 and rs1421085) showed decreased risk in females but increased risk in

males (**Figure 1C**). The other two loci (rs1229984 and rs28712821) showed decreased risk in

both sexes, but with significantly larger magnitudes in males.

Figure 1. Number of genome-wide significant loci and loci with sex-differentiated genetic effects. **A.** Bar plot with the number of independent genome-wide significant loci for each alcohol use phenotype in females (amber) and in males (blue) **B.** Miami plot displaying the 11 sex-stratified GWAS overlaid on top of each other in females (top, in amber) and in males (bottom, in blue). Sex-differentiated loci reaching genome-wide significance are annotated with the nearest gene and colored by alcohol use phenotype: *drinking frequency* (dark purple), *drinking quantity* (turquoise), *beer quantity* (green), and *PAU* (violet). Miami plots for all alcohol use phenotypes can be found in **Figure S3. C.** Forest plot showing odds ratios (OR) and 95% confidence intervals for the lead SNPs for the four loci with sex-differentiated effects. ORs are shown separately for females (amber diamonds) and males (blue squares), illustrating the direction and magnitude of association in each sex. The nearest gene is shown in parentheses.

Between-sex genetic correlations

Genetic correlations between sexes ranged from 0.68 ± 0.07 to 0.89 ± 0.04 (**Figure 2A**, **Table S4**). Consistent with our first hypothesis, drinking quantity phenotypes showed the lowest between-sex r_g average (mean r_g = 0.78 ± 0.06) compared to frequency (mean r_g = 0.87 ± 0.06) or problematic use (mean r_g = 0.85 ± 0.08). Of note, r_g values across drinking quantity phenotypes varied widely depending on the beverage types (from 0.70 ± 0.06 for *beer quantity* to 0.89 ± 0.04 for *red wine quantity*).

Genetic correlations among alcohol phenotypes

To test whether r_g patterns across alcohol use phenotypes differed by sex, we computed cross-trait r_g separately in males (r_{gM}) and females (r_{gF}). A total of 24 out of 55 (43.6%) trait-pair comparisons showed significant differences between sexes (**Figure 2B**, **Table S5**).

Thirteen significant pairs of traits showed consistent direction in r_g estimates in females and males but were of larger magnitude in one of the sexes. The greatest differences in r_g estimates were for *drinking quantity*/*white wine quantity*, which were stronger in females (r_{gF} = 0.68 vs. r_{gM} = 0.23) and *drinking quantity*/*beer quantity*, which were stronger in males (r_{gF} = 0.30 vs. r_{gM} = 0.72; **Figure 2B**, **Table S5**).

Two pairs of traits showed opposite direction in r_g estimates by sex: *drinking quantity*/*drinking with meals* were negatively genetically correlated in males but positively in females (r_{gF} = 0.17 vs. r_{gM} = -0.30), and *spirit quantity*/*red wine quantity* were positively genetically correlated in males but negatively in females (r_{gF} = -0.14 vs. r_{gM} = 0.13; **Figure 2B**, **Table S5**).

Nine pairs of traits showed significant r_g estimates in only one sex. For example, *white wine quantity*/*PAU* were positively genetically correlated in females but not in males (r_{gF} = 0.38 vs. r_{gM} = -0.08) and *drinking quantity*/*spirit quantity* were positively genetically correlated in males but not in females (r_{gF} = 0.07 vs. r_{gM} = 0.31; **Figure 2B**, **Table S5**).

Figure 2. Genetic correlation (r_g) estimates between sexes and among alcohol use phenotypes in females and males. **A.** Forest plot of between-sex r_g with 95% CI across the 11 alcohol use phenotypes. Alcohol use phenotypes are grouped by category: frequency, quantity, and problematic use. **B.** Network plot of cross-trait genetic correlations in females (upper) and males (lower) for trait pairs with statistically significant sex differences in r_g estimates. Edges represent pairwise genetic correlations: red edges indicate positive correlations, blue edges indicate negative correlations, and edge thickness reflects the absolute magnitude of r_g. Faint (lighter) edges denote correlations that were not statistically significant within the respective sex. 10 pairs of traits showed stronger r_g estimates in females and 12 pairs of traits showed stronger r_g estimates in males.

Genetic correlations with other complex traits

We calculated r_gs between alcohol use phenotypes in females and males and 71 other complex traits (**Table S6**). Of the r_g estimates that were significant in either sex, 18.6% showed significant sex differences. Of these, 50.4% were concordant (i.e., same direction) across sexes, 6% were discordant (i.e., opposite directions), 21.7% were significant only in females (i.e., female-specific), and 21.7% were significant only in males (i.e., male-specific; **Figure 3A**). Quantity phenotypes showed greater sex differences in r_g estimates compared to frequency or problematic use phenotypes (**Figure 3A**).

Figure 3. Genetic correlations (r_g) between alcohol use phenotypes in females and males and 71 traits from other published sex-combined GWAS. **A.** Bar plot summarizing the number of traits showing significant sex differences in the r_g estimates with each alcohol use phenotype. Results are categorized as: concordant (green) if significant in both sexes, with effects in the same direction; discordant (red) if significant in both sexes, but with effects in opposite directions; female-specific (amber) if significant only in females; and male-specific (blue) if significant only in males. No significant sex differences in r_g were observed for *drinking frequency*, *decreased drinking* or *binge drinking*. **B**. Heatmap displaying r_g estimates for 15 selected traits with significant sex differences (FDR corrected $p_{sex-diff} < 0.05$). Traits are grouped into four categories: externalizing, internalizing, cognitive and anthropometric (Anthro). Only values for statistically significant r_g estimates in each sex are shown. Cell color indicates the magnitude and direction of the correlation, ranging from blue (negative r_g) to white (null) to red (positive r_g). Cell outline indicates concordance, discordance, or sex-specificity as in panel A. ADHD: attention-deficit/hyperactivity disorder; PTSD: post-traumatic stress disorder.

307   **Figure 3B** shows a heatmap of r_g for selected traits with significant sex differences (FDR

308   corrected $p_{sex\text{-}diff} < 0.05$). We observed similar r_g patterns for overall *drinking quantity* and *PAU*;

309   but identified greater variability in r_g patterns when examining specific beverage types.

Substance use and externalizing traits

Our results were consistent with our second hypothesis, showing that r_gs with externalizing

traits are greater in males than in females. Among males we observed consistently stronger

positive r_gs between alcohol phenotypes and substance use traits compared to females. For

example, *drinking quantity* was more strongly positively genetically correlated in males with

general addiction (a genetically derived trait capturing shared liability to SUDs; $r_{gF} = 0.44$ vs. r_{gM}

= 0.56), tobacco use disorder ($r_{gF} = 0.14$ vs. $r_{gM} = 0.31$), and cannabis use disorder ($r_{gF} = 0.16$ vs.

$r_{gM} = 0.34$), and *PAU* was more strongly positively genetically correlated in males with tobacco

use disorder ($r_{gF} = 0.40$ vs. $r_{gM} = 0.59$) and opioid use disorder ($r_{gF} = 0.39$ vs. $r_{gM} = 0.76$). The r_gs

with externalizing traits were also stronger in males. For example, *drinking quantity* was more

strongly positively genetically correlated in males with externalizing psychopathology ($r_{gF} = 0.27$

vs. $r_{gM} = 0.36$), attention-deficit/hyperactivity disorder (**ADHD**; $r_{gM} = 0.09 \pm 0.03$ vs. -0.12 ± 0.03,

$p = 8.41e\text{-}05$), and antisocial behavior ($r_{gF} = -0.12$ vs. $r_{gM} = 0.25$), and *PAU* was more strongly

positively genetically correlated in males with delay discounting ($r_{gF} = -0.1$ vs. $r_{gM} = 0.20$). In

contrast, we observed sex-specific *negative r_gs* with externalizing traits for *drinking quantity* (e.g.,

delay discounting $r_{gF} = -0.20$ vs. $r_{gM} = 0.001$) in females.

For specific beverages, *beer quantity* was the only beverage in males that showed positive

r_gs with externalizing (e.g., general addiction ($r_{gF} = 0.42$ vs. $r_{gM} = 0.58$) and extraversion ($r_{gF} = -0.9$

vs. $r_{gM} = 0.12$)). On the contrary, *red wine quantity* (e.g., general addiction $r_{gF} = 0.01$ vs. $r_{gM} = -$

0.15) and *white wine quantity* showed negative r_gs with externalizing traits in males (e.g., general

addiction $r_{gF} = 0.25$ vs. $r_{gM} = -0.2$). In contrast, all r_gs with externalizing traits were positive in

females, particularly for *spirit quantity* (e.g., tobacco use disorder $r_{gF} = 0.39$ vs. $r_{gM} = 0.24$) and for

white wine quantity (e.g. general addiction $r_{gF} = 0.25$ vs. $r_{gM} = -0.20$).

Internalizing traits

Results for internalizing traits were broadly consistent with our second hypothesis of

stronger associations in females, but the evidence was modest. We observed female-specific r_gs

across only three traits. For *drinking quantity,* we observed female-specific negative r_gs with post-

traumatic stress disorder (PTSD; $r_{gF} = -0.13$ vs. r_{gM} 0.01) and loneliness ($r_{gF} = -0.18$ vs. $r_{gM} = -$

0.06). However, for specific beverage types, particularly for *beer quantity,* we observed a female-
specific positive r_g with ever self-harmed (r_{gF} = 0.39 vs. r_{gM} = 0.07).

Cognitive traits

For cognitive traits, r_g patterns were divergent across sexes for *drinking quantity* and *PAU*.
We observed male-specific negative r_gs with cognitive traits for *drinking quantity* (e.g., executive
function r_{gF} = 0.05 vs. r_{gM} = -0.08) and for *PAU* (e.g., educational attainment r_{gF} = -0.03 vs. r_{gM} = -
0.23). In contrast, we observed female-specific positive r_gs with cognitive and socioeconomic
traits for *drinking quantity* (e.g., educational attainment r_{gF} = 0.28 vs. r_{gM} = -0.03).

Sex differences in r_g patterns across cognitive traits varied across beverage types. In
males, we observed stronger negative r_g for *beer quantity* and educational attainment (r_{gF} = -0.20
vs. r_{gM} = -0.46) and executive function (r_{gF} = -0.07 vs. r_{gM} = -0.23), but stronger positive r_gs for *red*
wine quantity and executive function (r_{gF} = 0.09 vs. r_{gM} = 0.24) and for *white wine quantity* and
educational attainment (r_{gF} = 0.49 vs. r_{gM} = 0.67). In contrast, in females, we observed stronger
negative r_gs for *spirit quantity* and educational attainment (r_{gF} = -0.50 vs. r_{gM} = -0.15).

Anthropometric traits

353 In females, we observed a stronger negative r_g for *drinking quantity* and BMI than in males
354 (r_{gF} = -0.18 vs. r_{gM} = -0.07). However, when looking at the r_g for specific beverage types, the r_g
355 with BMI became positive for *spirit quantity* in females (r_{gF} = 0.37 vs. r_{gM} = 0.26), and for *beer*
356 *quantity* in males (r_{gF} = -0.05 vs. r_{gM} = 0.09).

Phenome-wide association studies

To test our third hypothesis that sex-specific PGS would uncover associations with sex-
specific comorbidities that may be masked in sex-agnostic analyses, we investigated sex
differences in comorbidity patterns between alcohol PGSs and other medical outcomes (**Table**
S7). Specifically, we tested female PGSs in the female sample, and male PGSs in the male
sample and benchmarked the results against the sex-combined PGSs in the full sample. Out of
the 1,112 traits tested, up to 487 traits were significantly associated with at least one alcohol use
PGS in at least one sex. Of these, 97 (19.9%) PGS-trait comparisons showed statistically
significant sex differences (**Figure 4A**): 41 (8.42%) were significant in females as well as in the
sex-combined samples (i.e., female specific); 15 (3.1%) were significant only in females (i.e.,
female unique); 32 (6.6%) were significant in males as well as in the sex-combined samples (i.e.,

male specific); 6 (1.2%) were significant only in males (i.e., male unique); and 5 (1%) were
concordant across sexes but showed stronger associations in males. No concordant trait
associations were stronger in females. **Figure 4B** shows the PGS associations for selected traits
with significant sex differences (FDR corrected $p_{sex\text{-}diff}$ < 0.05).

372
Figure 4. Phenome-wide association study (PheWAS) meta-analysis in BioVU and PMBB. **A.** Bar plot
summarizing the number of traits showing significant sex differences between the female-specific and the
male-specific polygenic scores (PGSs) associations across all alcohol use phenotypes. Results are
categorized as: female-specific (amber) if significant in the female-specific and sex-combined PGS
analyses; female-unique (dark amber) if significant only in the female-specific PGS analyses; male-specific
(blue) if significant in the male-specific and sex-combined PGS analyses; male-unique (dark blue) if
significant only in the male-specific PGS analyses; and concordant (green) if significant in both sexes, but
with stronger effects in males. *Drinking quantity* and *AUDIT total* PGSs exhibited the most female-specific
associations (15 and 14, respectively), while *beer quantity* and *PAU* exhibited the most male-specific

associations (19 and 6, respectively). No significant sex differences in r_g were observed for *drinking with*
meals and *binge drinking*. **B.** Associations between alcohol use phenotypes PGSs and selected medical
conditions across disease categories. PheWAS results are displayed for female PGS in the female target
sample (left), and male PGS in the male target sample (middle) PGSs. Odds ratios (OR) are shown for
selected phenotypes exhibiting sex-differentiated effects. Triangle direction indicates the direction of the
association (upward for OR > 1, downward for OR < 1), and triangle color corresponds to the alcohol use
phenotype used to construct the PGS. Filled triangles represent FDR-corrected significant associations,
while empty triangles indicate non-significant associations. Asterisks mark female and male PGS
associations that were not significant in the sex-combined PGS analyses (i.e., female-unique and male-
unique associations). The right panel displays the number of cases in each medical condition for females
(amber diamonds) and males (blue squares).

In the female PGS analyses, 14 (26%) of the sex-specific associations were positive (i.e.,
linked to increased risk for medical conditions), particularly for *drinking quantity* (n = 5) and *spirit*
quantity (n = 6) PGSs (**Figure 4A**). These included associations with higher risk for other SUDs
(e.g., tobacco use disorder (**TUD**; OR_F = 1.17 [1.13, 2.21])), musculoskeletal conditions (e.g.,
osteoarthritis (OR_F = 1.07 [1.03, 1.11])), dermatologic conditions (e.g., degenerative skin
conditions (OR_F = 1.12 [1.06, 1.18])), genitourinary conditions (e.g., end stage renal disease (OR_F
= 1.16 [1.08, 1.24])), and circulatory conditions (e.g., heart failure (OR_F = 1.08 [1.04, 1.11]); **Figure**
4B). Four of these associations were not significant in the sex-combined PGS analyses (**Table**
S7).

In females, we also observed 40 (74%) negative associations (i.e., linked to reduced risk
for medical conditions), particularly for *drinking frequency* (n = 9)*, drinking quantity* (n = 14) and
AUDIT total (n = 14) PGS (**Figure 4A**). These included associations with lower risk for digestive
diseases (e.g., chronic liver disease and cirrhosis (OR_F = 0.91 [0.85, 0.97])), neurological (e.g.,
sleep apnea (OR_F = 0.88 [0.84, 0.92])), endocrine (e.g., type 2 diabetes (OR_F = 0.87 [0.83, 0.91])),
circulatory conditions (e.g., ischemic heart disease (OR_F = 0.92 [0.88, 0.96])), dermatologic
conditions (e.g., psoriatic arthropathy (OR_F = 0.77 [0.61, 0.93])), genitourinary (e.g., renal failure
(OR_F = 0.95 [0.93, 0.97])), and hematopoietic conditions (e.g., diseases of white blood cells (OR_F
= 0.92 [0.86, 0.98]); **Figure 4B**, **Table S7**). Eleven of these associations were not significant in
the sex-combined PGS analyses (**Table S7**), reflecting the importance of conducting sex-specific
analyses.

In the male PGS analyses, 31 (81.6%) of the sex-specific associations were positive,
particularly for *beer quantity* (n = 19) and *PAU* (n = 6) PGSs (**Figure 4A**). These included
associations with higher risk for SUDs (e.g., TUD (OR_M = 1.21 [1.15, 1.27])), mental conditions
(e.g., anxiety (OR_M = 1.12 [1.08, 1.16]), as well as medical comorbidities that result from
substance use, such as digestive conditions (e.g., alcoholic liver damage (OR_M = 1.59 [1.43,

1.75])), genitourinary conditions (e.g., renal failure (OR_M = 1.09 [1.05, 1.13])), hematopoietic

conditions (e.g., thrombocytopenia (OR_M = 1.16 [1.08, 1.24])), infectious diseases (e.g., viral

hepatitis C (OR_M = 1.37 [1.25, 1.49])), neoplasm diseases (e.g., liver cancer (OR_M = 1.31 [1.15,

1.47])), and respiratory diseases (e.g., chronic airway obstruction (OR_M = 1.14 [1.08, 1.2]); **Figure**

4B, **Table S7**). Four of these associations were not significant in the sex-combined PGS analyses

(**Table S7**).

In males, only seven (18.4%) sex-specific associations were negative, including

associations with lower risk for digestive diseases (i.e., celiac disease (OR_M = 0.66 [0.5, 0.82]))

and endocrine and metabolic conditions (i.e., type 1 diabetes (OR_M = 0.91 [0.85, 0.97])), and

neoplasm diseases (i.e., hemangioma and lymphangioma (OR_M = 0.77 [0.63, 0.91])). Two of

these associations were not significant in the sex-combined PGS analyses (**Table S7**).

Finally, five associations were positively associated in both sexes but showed significantly

stronger associations in males, particularly for *PAU* (n = 4) and *beer quantity* (n = 1) PGS and

substance use traits (e.g., AUD (OR_F = 1.18 [1.08, 1.28] vs. OR_M = 1.41 [1.35, 1.47]); **Figure 4A-**

B, **Table S7**).

To assess whether sex-specific PGS improved prediction of AUD diagnosis, we compared

the variance explained (Nagelkerke R^2) by sex-specific and sex-combined PGS. Consistent with

our third hypothesis, sex-specific PGSs did not outperform the sex-combined PGSs in predicting

AUD in either the female or male samples (**Figure 5**, **Tables S7-8**). In fact, several sex-specific

PGSs (i.e., *drinking with meals, decreased drinking, spirits, red* and *white wine quantity and*

AUDIT total) were not significantly associated with AUD in either sex (**Table S7**).

Figure 5. Predictive ability assessment of sex-specific and sex-combined polygenic scores (PGS) for alcohol use phenotypes on alcohol use disorder (AUD) diagnosis in BioVU and PMBB. **A.** Odds ratios (OR) and 95% confidence intervals for the association between each alcohol use phenotype PGS and AUD Phecode in sex-stratified target samples. **B.** Weighted average Nagelkerke-R^2 values for each PGS in predicting AUD in BioVU and PMBB. The weighted average Nagelkerke R^2 across sites was calculated with the formula Nagelkerke-R^2_{WA} = $\sum w_i * R_i^2 / \sum w_i$. The range corresponds to minimum and maximum Nagelkerke R^2 across sites (see **Table S8**). Male-specific PGS are in blue squares, sex-combined PGS in males are in dark blue squares, female-specific PGS are in amber triangles, and sex-combined PGS in females are in dark amber triangles. Only alcohol use phenotype for which the PGS showed a significant association with AUD in either of the sex-specific PGSs are displayed. *Drinking with meals, decreased drinking*, *spirits, red* and *white wine quantity* and *AUDIT total* PGSs were not significantly associated with AUD in either sex (**Table S7**).

DISCUSSION

Sex differences in alcohol use patterns and trajectories are well documented, but the biological mechanisms underpinning these differences are relatively unknown[7]. Using sex-stratified GWAS of alcohol use behaviors spanning measures of frequency, quantity and problematic use, we characterized their genetic architecture separately in females and males. We evaluated both *quantitative* sex differences (i.e., the magnitude of genetic influence by sex) and *qualitative* differences (i.e., specific genetic variants). Our findings supported our original hypotheses: (i) quantitative sex differences were broadly more pronounced for drinking quantity

phenotypes, but less notable for frequency or problematic use, (ii) externalizing comorbidities
showed stronger genetic correlations in males with less evidence for stronger genetic correlations
with internalizing comorbidities in females, and (iii) sex-specific PGSs revealed associations with
sex-specific comorbidities, some of which were masked in sex-agnostic analyses. We argue that
phenotypes strongly influenced by cultural and social differences, particularly the choice of
beverage, shapes these sex-specific comorbidity patterns, and outline considerations for future
sex-aware studies of alcohol use phenotypes.

Genetic and environmental factors jointly shape alcohol use behaviors. Twin studies have
repeatedly shown that alcohol use behaviors are heritable, but evidence for large quantitative sex
differences in heritability remains limited (40-45% in females, 50-52% in males;[21,54–58]. Our GWAS
results are largely consistent with these findings. We identified significant h^2_{SNP} for all 11
phenotypes, with similar estimates across sexes for most traits. This aligns with prior UK Biobank
analyses showing minimal cross-sex divergence in h^2_{SNP} estimates across hundreds of other
complex traits, including psychiatric and behavioral phenotypes[59]. Thus, data both from family
studies and GWAS suggest that the overall genetic contribution to alcohol use behaviors is
broadly similar by sex.

Despite this broad similarity, important sex differences still emerged in our study for *beer*
quantity and *PAU*, which showed significantly higher h^2_{SNP} in males compared to females.
Because heritability depends on the study population and measurement[59,60], these gaps may
reflect non-genetic influences, such as sample imbalance (e.g., 496,548 males vs. 143,198
females for *PAU*), differences in endorsement likely reflecting differences in social norms (e.g.,
UK Biobank male participants reported drinking ~5x more beer compared to females), or reporting
biases (e.g., due to stigma surrounding alcohol use in females)[61,62]. Therefore, these differences
should be interpreted with caution until replicated in balanced cohorts with harmonized measures.

Over the past decade, sex-agnostic GWASs have identified hundreds of loci associated
with aspects of alcohol use behaviors[40,63–65]. When conducting GWAS in sex-stratified cohorts,
we identified that sex-differentiated effects existed but were sparse. While the magnitude of effect
across variants was largely concordant across sexes, we found four loci with significant sex
differences: a female-specific association in *IZUMO1* (rs838147) for *drinking frequency* and
quantity, and three male-specific associations in *ADH1B* (rs1229984), *KLB* (rs28712821), and
FTO (rs1421085) for *beer quantity* and/or *PAU*. However, there are two caveats to note. First, it
is possible that differences in ascertainment biases may be again conflating the findings. For

example, *ADH1B*, one of the most well-established genes implicated in alcohol use and AUD,
shows robust associations with several alcohol use phenotypes in females, suggesting that the
male-specific association observed for *beer quantity* may instead reflect reduced power in the
female sample for this particular phenotype rather than true sex-differentiated genetic effects. In
addition, a recent study using UK Biobank data identified a BMI-increasing *FTO* allele
(rs10468280) to be at a higher frequency in males and more strongly associated with BMI in
males, consistent with sex-differential participation bias[66]. Similarly, we identified an *FTO* variant
in high LD (r^2 = 0.9) with rs10468280 that showed sex-differentiated genetic effects in males for
PAU, which may reflect similar selection biases rather than biology. Second, sex-stratified
GWASs can only substitute genotype-by-sex interaction tests when covariate interactions and
variance differences are equivalent in the two sexes. Therefore, individual-level data and
genotype-by-sex interaction test will be ultimately needed to evaluate whether these reported sex
differences are driven by genetic or non-genetic factors[67]. Overall, the absence of sex-
differentiated loci for the remaining alcohol phenotypes may partly reflect limited statistical power
rather than proof of homogeneity[68]. Indeed, sex-differentiated effects are now beginning to
emerge for large-scale GWAS of somatic traits[69]. It is plausible that, for alcohol use phenotypes,
as seen for other complex behavioral and psychiatric traits[70], much larger and more balanced
samples will be needed to detect sex-differentiated genetic effects, which, even if small, could be
informative for mechanism and comorbidity.

Equal h^2_{SNP} across sexes and limited genome-wide sex-differentiated effects do not imply
that the underlying polygenic architecture is shared in females and males[41]. In our data, between-
sex genetic correlations significantly departed from 1.0, suggesting that sex-differentiated genetic
effects for the alcohol phenotypes tested are prevalent but small in magnitude and distributed
across the genome[22,26,71]. Mean r_g values were generally lower for quantity phenotypes (mean r_g
= 0.87 ± 0.06 [frequency], 0.78 ± 0.06 [quantity] and 0.85 ± 0.08 [problematic use]). Differences
were particularly pronounced for certain quantity measures, particularly *spirit quantity and beer*
quantity (r_g = 0.68 and 0.70), but less for others, such as *red wine quantity* (r_g = 0.89), perhaps
reflecting cultural or social differences in drinking behaviors around these specific beverages.

Cross-trait genetic correlations among alcohol phenotypes also differed between sexes:
43% of pairwise comparisons showed sex divergence, with some showing opposite patterns in
males and in females. For instance, *drinking quantity* and *drinking with meals* were negatively
genetically correlated in males, but positively in females. Males reported consuming larger
quantities of alcohol on average (2.81 ± 1.00 vs. 2.12 ± 1.01), yet they were less likely to drink with

meals (58.5% vs. 77.6%) compared to females. Thus, in males, drinking quantity likely reflects
higher-volume drinking episodes outside mealtimes (often involving beer). Furthermore, even with
the same number of drinks, females can reach higher blood alcohol concentrations due to lower
total body water content[17,27]. These patterns in behavior, physiological and reporting differences
can bias genetic correlation estimates. Scaling measures of intake (g of ethanol/kg), modeling
beverage and meal context, and testing methods that use multimodal techniques (e.g., Genomic
SEM) to account for participation bias by sex[26,66] could clarify whether the observed sex-
dependent patterns reflect biological or environmental differences.

When examining the relationship between female and male alcohol use behaviors and
other comorbid traits, 18.6% of the genetic correlations that were significant in either males or
females showed significant sex differences. We identified patterns partially consistent with our
second hypothesis. In males, genetic correlations with externalizing traits (e.g., SUDs, ADHD,
externalizing, extraversion or delay discounting) were stronger for *drinking quantity, beer quantity*
and *PAU* compared to females. In females, we identified a single stronger genetic correlation with
an internalizing trait (i.e., self-harm) for *beer quantity*, suggesting that the previously observed
higher comorbidity with internalizing psychopathology in females[28,72] may be largely influenced by
environmental or social factors rather than genetic influences. These patterns are consistent with
epidemiologic and twin evidence[73,74], reinforcing that AUD likely develops through partly different
etiologic pathways in females and males.

Once more, the largest sex differences were found for overall drinking quantity rather than
frequency or problematic use phenotypes and varied by beverage type. For example, *beer*
quantity showed *positive* genetic correlations for externalizing traits in males, whereas *spirit*
quantity showed *positive* genetic correlations for the same externalizing traits in females. In
contrast, *red* and *white wine quantity* in males showed *negative* genetic correlations with
externalizing traits. These findings may reflect cultural factors, including social norms, surrounding
alcohol consumption, rather than purely biological differences. Furthermore, we identified positive
genetic correlations with *better* socioeconomic outcomes for overall drinking quantity in females
only, and for red and white wine consumption in both sexes. This suggests that the counterintuitive
positive genetic correlations that we and others have previously noted between *better* socio-
educational outcomes and alcohol consumption in sex-combined samples, which likely reflects
collider bias from nonrandom sampling in biobank studies[75–78], may be largely driven by females
and/or by specific beverage types, particularly wine, which is often a marker for higher

socioeconomic status. Future work should account for beverage preference to avoid masking or
mischaracterizing sex-differentiated effects.

559   In hospital-based cohorts, PGS analyses revealed sex-specific associations with alcohol-
related medical comorbidities. Across BioVU and PMBB, 19.9% PGS-trait comparisons showed
significant sex differences. These differences are unlikely to be simply a power artifact, because
target-sample sizes by sex were comparable for most traits. In females, female-specific PGS were
associated with increased risk of osteoarthritis, degenerative skin conditions, cardiomegaly, and
end-stage renal disease, among others. In contrast, male-specific PGS associations concentrated
in SUDs, alcohol-related medical sequelae (e.g., alcoholic liver damage, liver cancer), and other
externalizing-related traits (i.e., fracture of lower limb), consistent with the epidemiological
literature reporting heavier drinking and higher externalizing behaviors in males[79,80]. Strikingly,
some of these associations, such as the female-specific association with osteoarthritis and the
male-specific association with fracture of the lower limb, were not detected in sex-combined PGS
analyses, highlighting the importance of sex-stratified approaches for uncovering sex-specific
comorbidity profiles of alcohol use behaviors that were masked in sex-combined analyses. We
also observed *negative* PGS associations, primary between *drinking frequency* PGS and some
medical conditions, including circulatory, metabolic, respiratory and digestive conditions (**Figure
S7**), which persisted after covarying for AUD diagnosis in sensitivity analyses (**Table S9**). This
pattern of paradoxical associations is unlikely to reflect true protective biological effects. In fact,
phenotypic PheWAS of AUD in these same clinical populations did not recapitulate these
patterns, instead showing positive associations with these conditions (**Table S10**). Together,
these findings suggest that the apparent pattern of *protective* associations may reflect
participation biases from the healthier than average UK Biobank[81] discovery GWAS used to
construct the PGS, rather than true inverse biological relationships.

581   Sex-stratified PGS did not outperform sex-combined PGS for AUD prediction, consistent
582   with the idea that pooling females and males to compute PGSs often yields more precise SNP
583   weights when cross-sex genetic overlap is substantial (r_g 0.7–0.9)[82]. As larger and more balanced
584   sex-stratified GWAS become available, emerging approaches that jointly model genetic effects
585   across sexes (e.g., PRS-CSx)[74,82,83] can be applied to examine whether these approaches show
586   better predictive performance in females and males.

587   Our study is not without limitations. First, GWAS are disproportionately male-dominant,
especially for PAU, reflecting historical prevalence differences or ascertainment bias. This sample

imbalance can result in power differences and inflate apparent male effects. Second, many sex-
stratified alcohol GWAS were derived from volunteer cohorts (e.g., UK Biobank), where sex-
differential participation can induce or magnify cross-trait correlations[60,84]. Consumption
phenotypes from volunteer cohorts may benefit from multivariate frameworks (e.g., Genomic
SEM) to partial out shared structure not directly related to AUD liability, as we have shown in prior
work[25]. Third, sex differences are unlikely to be explained solely by common autosomal variation.
Although GWAS using UKB Biobank and 23andMe data included the X chromosome, X-aware
tools (e.g., methods accounting for X-inactivation, such as GXwasR[85], and rare-variant models
are needed to test whether non-autosomal or rare variation contributes to sex differences[60].
Finally, gene-by-environment interactions likely contribute to sex differences: genetic influences
on alcohol use often strengthen in permissive contexts (e.g., peer drinking, low
relationship/support), and attenuate in restrictive contexts (e.g., non-drinking peers or medical
advice)[86], with some evidence showing that this effect is stronger in females[20,87]. In addition, social
norms and behaviors surrounding alcohol consumption in the UK, where much of our data
originate, likely differ across countries, ages and historical moments. Future work should include
frameworks for quantifying and estimating polygenic GxE by sex, as well as incorporate data from
diverse sociocultural settings[88].

In summary, sex differences in the genetic architecture of alcohol use phenotypes are
polygenic and subtle, with little evidence for single variants with large sex-differentiated effects.
Patterns of genetic correlation with psychiatric traits and medical outcomes were sex-specific,
even when SNP-based heritability and genetic loci were mostly similar across sexes. The most
pronounced sex differences were observed for drinking quantity measures and were influenced
by beverage type. This work continues to motivate sex-aware analyses that consider the spectrum
of alcohol use behaviors and environmental information in larger, balanced cohorts. Adopting
these practices will enable future genetic studies that address, rather than ignore, AUD
heterogeneity in females and males.

Acknowledgements

This work was supported by National Institutes of Health grant numbers DP1DA054394 (JJM, SSR), T32GM139790 (JG), R25MH081482 (LV-R) and K01DA051759 (ECJ), by the National Institute of Mental Health grant numbers R01MH137219-01 (SSR), R01MH137220-01 (LKD) and R01-MH137212-01 (RLK), by the Tobacco-Related Disease Research Program grant numbers T35FT9589 (LV-R), T33KT6694 (NC-K) and T35MS9695 (NC-K), and the National Institute on Alcohol Abuse and Alcoholism grant number L40AA031140 (NC-K).

We would like to thank the research participants and employees of 23andMe Research Institute for making this work possible. The following members of the 23andMe Research Team contributed to this study: Stella Aslibekyan, Adam Auton, Elizabeth Babalola, Robert K. Bell, Jessica Bielenberg, Ninad S. Chaudhary, Zayn Cochinwala, Sayantan Das, Emily DelloRusso, Payam Dibaeinia, Sarah L. Elson, Nicholas Eriksson, Chris Eijsbouts, Teresa Filshtein, Pierre Fontanillas, Davide Foletti, Will Freyman, Zach Fuller, Julie M. Granka, Chris German, Éadaoin Harney, Alejandro Hernandez, Barry Hicks, David A. Hinds, M. Reza Jabalameli, Ethan M. Jewett, Yunxuan Jiang, Sotiris Karagounis, Lucy Kaufmann, Matt Kmiecik, Katelyn Kukar, Alan Kwong, Keng-Han Lin, Yanyu Liang, Bianca A. Llamas, Aly Khan, Steven J. Micheletti, Matthew H. McIntyre, Meghan E. Moreno, Priyanka Nandakumar, Dominique T. Nguyen, Jared O'Connell, Steve Pitts, G. David Poznik, Alexandra Reynoso, Shubham Saini, Morgan Schumacher, Leah Selcer, Anjali J. Shastri, Jingchunzi Shi, Suyash Shringarpure, Keaton Stagaman, Teague Sterling, Qiaojuan Jane Su, Joyce Y. Tung, Susana A. Tat, Vinh Tran, Xin Wang, Wei Wang, Catherine H. Weldon, Amy L. Williams, Peter Wilton.

We acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the patient- participants of Penn Medicine who consented to participate in this research program. We would also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol# 813913 and supported by Perelman School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878.

Conflict of interest

645   S.L.E. and P.F. were employed by and held stock or stock options in 23andMe, Inc. at the time of

646   the study. N.C.K. is consultant and holds stock options in CARI Health, Inc. All other authors

647   report no biomedical financial interests or potential conflicts of interest.

REFERENCES

1. Witkiewitz, K., Litten, R. Z. & Leggio, L. Advances in the science and treatment of alcohol use disorder. *Sci. Adv.* **5**, eaax4043 (2019).

2. Park, S. H. & Kim, D. J. Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies. *Clin. Mol. Hepatol.* **26**, 652–661 (2020).

3. Sanchez-Roige, S., Palmer, A. A. & Clarke, T.-K. Recent Efforts to Dissect the Genetic Basis of Alcohol Use and Abuse. *Biol. Psychiatry* **87**, 609–618 (2020).

4. Åberg, F., Byrne, C. D., Pirola, C. J., Männistö, V. & Sookoian, S. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. *J. Hepatol.* **78**, 191–206 (2023).

5. Castillo-Carniglia, A., Keyes, K. M., Hasin, D. S. & Cerdá, M. Psychiatric comorbidities in alcohol use disorder. *Lancet Psychiatry* **6**, 1068–1080 (2019).

6. Hendriks, H. F. J. Alcohol and Human Health: What Is the Evidence? *Annu. Rev. Food Sci. Technol.* **11**, 1–21 (2020).

7. Salvatore, J. E., Cho, S. B. & Dick, D. M. Genes, Environments, and Sex Differences in Alcohol Research. *J. Stud. Alcohol Drugs* **78**, 494–501 (2017).

8. Hernandez-Avila, C. A., Rounsaville, B. J. & Kranzler, H. R. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. *Drug Alcohol Depend.* **74**, 265–272 (2004).

9. Boykoff, N. *et al.* Gender Differences in the Relationship between Depressive Symptoms and Cravings in Alcoholism. *Am. J. Addict. Am. Acad. Psychiatr. Alcohol. Addict.* **19**, 352–356 (2010).

10. Peltier, M. R. *et al.* Sex differences in stress-related alcohol use. *Neurobiol. Stress* **10**, 100149 (2019).

11. Baros, A. M., Latham, P. K. & Anton, R. F. Naltrexone and cognitive behavioral therapy for

the treatment of alcohol dependence: do sex differences exist? *Alcohol. Clin. Exp. Res.* **32**,

771–776 (2008).

12. Dawson, D. A., Goldstein, R. B., Moss, H. B., Li, T.-K. & Grant, B. F. Gender differences in

the relationship of internalizing and externalizing psychopathology to alcohol dependence:

Likelihood, expression and course. *Drug Alcohol Depend.* **112**, 9–17 (2010).

13. Karpyak, V. M. *et al.* Gender-specific effects of comorbid depression and anxiety on the

propensity to drink in negative emotional states. *Addict. Abingdon Engl.* **111**, 1366–1375

(2016).

14. Rehm, J. *et al.* The relationship between different dimensions of alcohol use and the burden

of disease-an update. *Addict. Abingdon Engl.* **112**, 968–1001 (2017).

15. Szabo, G. Women and alcoholic liver disease - warning of a silent danger. *Nat. Rev.*

Gastroenterol. Hepatol. **15**, 253–254 (2018).

16. Agabio, R., Campesi, I., Pisanu, C., Gessa, G. L. & Franconi, F. Sex differences in

substance use disorders: focus on side effects. *Addict. Biol.* **21**, 1030–1042 (2016).

17. Erol, A. & Karpyak, V. M. Sex and gender-related differences in alcohol use and its

consequences: Contemporary knowledge and future research considerations. *Drug Alcohol*

Depend. **156**, 1–13 (2015).

18. Mancinelli, R., Vitali, M. & Ceccanti, M. Women, alcohol and the environment: an update

and perspectives in neuroscience. *Funct. Neurol.* **24**, 77–81 (2009).

19. Parés, A., Caballería, J., Bruguera, M., Torres, M. & Rodés, J. Histological course of

alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. *J. Hepatol.* **2**,

33–42 (1986).

20. Maxwell, A. M., Harrison, K., Rawls, E. & Zilverstand, A. Gender Differences in the

Psychosocial Determinants Underlying the Onset and Maintenance of Alcohol Use Disorder.

Front. Neurosci. **16**, 808776 (2022).

21. Prescott, C. A. Sex differences in the genetic risk for alcoholism. *Alcohol Res. Health J.*

Natl. Inst. Alcohol Abuse Alcohol. **26**, 264–273 (2002).

22. Zhou, H. *et al.* Multi-ancestry study of the genetics of problematic alcohol use in over 1

million individuals. *Nat. Med.* **29**, 3184–3192 (2023).

23. Kember, R. L. *et al.* Genetic Underpinnings of the Transition From Alcohol Consumption to

Alcohol Use Disorder: Shared and Unique Genetic Architectures in a Cross-Ancestry

Sample. *Am. J. Psychiatry* **180**, 584–593 (2023).

24. Kranzler, H. R., Zhou, H. & Kember, R. L. Identifying and Reducing Bias in Genome-Wide

Association Studies of Alcohol-Related Traits. *Am. J. Psychiatry* **179**, 14–16 (2022).

25. Mallard, T. T. *et al.* Item-Level Genome-Wide Association Study of the Alcohol Use

Disorders Identification Test in Three Population-Based Cohorts. *Am. J. Psychiatry* **179**, 58–

70 (2022).

26. Savage, J. E. *et al.* Genetic Heterogeneity Across Dimensions of Alcohol Use Behaviors.

Am. J. Psychiatry **181**, 1006–1017 (2024).

27. Mumenthaler, M. S., Taylor, J. L., O'Hara, R. & Yesavage, J. A. Gender differences in

moderate drinking effects. *Alcohol Res. Health J. Natl. Inst. Alcohol Abuse Alcohol.* **23**, 55–

64 (1999).

28. Farhane-Medina, N. Z., Luque, B., Tabernero, C. & Castillo-Mayén, R. Factors associated

with gender and sex differences in anxiety prevalence and comorbidity: A systematic review.

Sci. Prog. **105**, 368504221135469 (2022).

29. Meyers, J. L. *et al.* Genetic Influences on Alcohol Use Behaviors Have Diverging

Developmental Trajectories: A Prospective Study among Male and Female Twins. *Alcohol.*

Clin. Exp. Res. **38**, 2869–2877 (2014).

30. Jinwala, Z. *et al.* Predicting treatment-seeking status for alcohol use disorder using

polygenic scores and machine learning in a deeply-phenotyped sample. *Drug Alcohol*

Depend. **274**, 112797 (2025).

31. Lai, D. *et al.* Alcohol Use Disorder Polygenic Score Compared With Family History and

ADH1B. *JAMA Netw. Open* **7**, e2452705 (2024).

32. Lin, B., Paterson, A. D. & Sun, L. Better together against genetic heterogeneity: A sex-

combined joint main and interaction analysis of 290 quantitative traits in the UK Biobank.

PLoS Genet. **20**, e1011221 (2024).

33. Miller, A. P. *et al.* Diagnostic Criteria for Identifying Individuals at High Risk of Progression

From Mild or Moderate to Severe Alcohol Use Disorder. *JAMA Netw. Open* **6**, e2337192

(2023).

34. Lee, J. J., McGue, M., Iacono, W. G. & Chow, C. C. The accuracy of LD Score regression

as an estimator of confounding and genetic correlations in genome-wide association

studies. *Genet. Epidemiol.* **42**, 783–795 (2018).

35. National Academies of Sciences, Engineering & Medicine. *Using Population Descriptors in*

Genetics and Genomics Research: A New Framework for an Evolving Field. (The National

Academies Press, Washington, DC, 2023). doi:10.17226/26902.

36. *Rethinking Race and Ethnicity in Biomedical Research*. (National Academies Press,

Washington, D.C., 2025). doi:10.17226/27913.

37. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity

in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

38. Deak, J. D. *et al.* Genome-Wide Investigation of Maximum Habitual Alcohol Intake in US

Veterans in Relation to Alcohol Consumption Traits and Alcohol Use Disorder. *JAMA Netw.*

Open **5**, e2238880 (2022).

39. Kranzler, H. R. *et al.* Genome-wide association study of alcohol consumption and use

disorder in 274,424 individuals from multiple populations. *Nat. Commun.* **10**, 1499 (2019).

40. Sanchez-Roige, S. *et al.* Genome-Wide Association Study Meta-Analysis of the Alcohol Use

Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. *Am. J. Psychiatry*

176, 107–118 (2019).

41. Khramtsova, E. A. *et al.* Quality control and analytic best practices for testing genetic

models of sex differences in large populations. *Cell* **186**, 2044–2061 (2023).

42. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of

genomewide association scans. *Bioinforma. Oxf. Engl.* **26**, 2190–2191 (2010).

43. Carroll, R. J., Bastarache, L. & Denny, J. C. R PheWAS: data analysis and plotting tools for

phenome-wide association studies in the R environment. *Bioinforma. Oxf. Engl.* **30**, 2375–

2376 (2014).

44. Roden, D. M. *et al.* Development of a large-scale de-identified DNA biobank to enable

personalized medicine. *Clin. Pharmacol. Ther.* **84**, 362–369 (2008).

45. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat. Genet.* **48**,

1284–1287 (2016).

46. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.

Nature **526**, 68–74 (2015).

47. Dennis, J. *et al.* Genetic risk for major depressive disorder and loneliness in sex-specific

associations with coronary artery disease. *Mol. Psychiatry* **26**, 4254–4264 (2021).

48. Loh, P.-R. *et al.* Reference-based phasing using the Haplotype Reference Consortium

panel. *Nat. Genet.* **48**, 1443–1448 (2016).

49. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer

datasets. *GigaScience* **4**, 7 (2015).

50. Price, A. L. *et al.* Principal components analysis corrects for stratification in genome-wide

association studies. *Nat. Genet.* **38**, 904–909 (2006).

51. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via

Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).

52. Zhang, D. rsq: R-Squared and Related Measures. (2024).

53. Pasaniuc, B. & Price, A. L. Dissecting the genetics of complex traits using summary

association statistics. *Nat. Rev. Genet.* **18**, 117–127 (2017).

54. de Moor, M. H. M. *et al.* Heritability of problem drinking and the genetic overlap with

personality in a general population sample. *Front. Genet.* **2**, 76 (2011).

55. Kendler, K. S., Myers, J., Dick, D. & Prescott, C. A. The Relationship Between Genetic

Influences on Alcohol Dependence and on Patterns of Alcohol Consumption. *Alcohol. Clin.*

Exp. Res. **34**, 1058–1065 (2010).

56. Stringer, S., Polderman, T. J. C. & Posthuma, D. Majority of human traits do not show

evidence for sex-specific genetic and environmental effects. *Sci. Rep.* **7**, 8688 (2017).

57. van Beek, J. H. D. A. *et al.* Stable Genetic Effects on Symptoms of Alcohol Abuse and

Dependence from Adolescence into Early Adulthood. *Behav. Genet.* **42**, 40–56 (2012).

58. Verhulst, B., Neale, M. C. & Kendler, K. S. The heritability of alcohol use disorders: a meta-

analysis of twin and adoption studies. *Psychol. Med.* **45**, 1061–1072 (2015).

59. Ge, T., Chen, C.-Y., Neale, B. M., Sabuncu, M. R. & Smoller, J. W. Phenome-wide

heritability analysis of the UK Biobank. *PLoS Genet.* **13**, e1006711 (2017).

60. Martin, J. *et al.* Examining Sex-Differentiated Genetic Effects Across Neuropsychiatric and

Behavioral Traits. *Biol. Psychiatry* **89**, 1127–1137 (2021).

61. Gomez, K. U., Goodwin, L., Chisholm, A. & Rose, A. K. Alcohol use during pregnancy and

motherhood: Attitudes and experiences of pregnant women, mothers, and healthcare

professionals. *PLOS ONE* **17**, e0275609 (2022).

62. Stringer, K. L. & Baker, E. H. Stigma as a Barrier to Substance Abuse Treatment Among

Those With Unmet Need: An Analysis of Parenthood and Marital Status. *J. Fam. Issues* **39**,

3–27 (2018).

63. Deak, J. D., Miller, A. P. & Gizer, I. R. Genetics of alcohol use disorder: a review. *Curr.*

Opin. Psychol. **27**, 56–61 (2019).

64. Johnson, E. C. *et al.* The collaborative study on the genetics of alcoholism: Genetics. *Genes*

Brain Behav. **22**, e12856 (2023).

65. Mallard, T. T. & Sanchez-Roige, S. Dimensional Phenotypes in Psychiatric Genetics:

Lessons from Genome-Wide Association Studies of Alcohol Use Phenotypes. *Complex*

Psychiatry **7**, 45–48 (2021).

66. Pirastu, N. *et al.* Genetic analyses identify widespread sex-differential participation bias.

Nat. Genet. **53**, 663–671 (2021).

67. Zhou, H. *et al.* Genotype-by-sex interaction analyses for alcohol use disorder across

biobanks. *Alcohol Clin. Exp. Res.* https://doi.org/10.1111/acer.70173 (2025)

doi:10.1111/acer.70173.

68. Boraska, V. *et al.* Genome-wide meta-analysis of common variant differences between men

and women. *Hum. Mol. Genet.* **21**, 4805–4815 (2012).

69. Winkler, T. W. *et al.* The Influence of Age and Sex on Genetic Associations with Adult Body

Size and Shape: A Large-Scale Genome-Wide Interaction Study. *PLoS Genet.* **11**,

e1005378 (2015).

70. Blokland, G. A. M. *et al.* Sex-Dependent Shared and Nonshared Genetic Architecture

Across Mood and Psychotic Disorders. *Biol. Psychiatry* **91**, 102–117 (2022).

71. Bernabeu, E. *et al.* Sex differences in genetic architecture in the UK Biobank. *Nat. Genet.*

53, 1283–1289 (2021).

72. Gutman, L. M. & Codiroli McMaster, N. Gendered Pathways of Internalizing Problems from

Early Childhood to Adolescence and Associated Adolescent Outcomes. *J. Abnorm. Child*

Psychol. **48**, 703–718 (2020).

73. Gui, Y. *et al.* Sex-specific genetic association between psychiatric disorders and cognition,

behavior and brain imaging in children and adults. *Transl. Psychiatry* **12**, 347 (2022).

74. Merikangas, A. K. & Almasy, L. Using the tools of genetic epidemiology to understand sex

differences in neuropsychiatric disorders. *Genes Brain Behav.* **19**, e12660 (2020).

75. Collins, S. E. Associations Between Socioeconomic Factors and Alcohol Outcomes. *Alcohol*

Res. Curr. Rev. **38**, 83–94 (2016).

76. Fry, A. *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK

Biobank Participants With Those of the General Population. *Am. J. Epidemiol.* **186**, 1026–

1034 (2017).

77. Rosoff, D. B. *et al.* Educational attainment impacts drinking behaviors and risk for alcohol

dependence: results from a two-sample Mendelian randomization study with ~780,000

participants. *Mol. Psychiatry* **26**, 1119–1132 (2021).

78. Swanson, J. M. The UK Biobank and selection bias. *The Lancet* **380**, 110 (2012).

79. Dir, A. L., Bell, R. L., Adams, Z. W. & Hulvershorn, L. A. Gender Differences in Risk Factors

for Adolescent Binge Drinking and Implications for Intervention and Prevention. *Front.*

Psychiatry **8**, 289 (2017).

80. Hicks, B. M. *et al.* Gender Differences and Developmental Change in Externalizing

Disorders From Late Adolescence to Early Adulthood: A Longitudinal Twin Study. *J.*

Abnorm. Psychol. **116**, 433–447 (2007).

81. Schoeler, T. *et al.* Participation bias in the UK Biobank distorts genetic associations and

downstream analyses. *Nat. Hum. Behav.* **7**, 1216–1227 (2023).

82. Zhang, C., Ye, Y. & Zhao, H. Comparison of Methods Utilizing Sex-Specific PRSs Derived

From GWAS Summary Statistics. *Front. Genet.* **13**, 892950 (2022).

83. Silveira, P. P., Pokhvisneva, I., Howard, D. M. & Meaney, M. J. A sex-specific genome-wide

association study of depression phenotypes in UK Biobank. *Mol. Psychiatry* **28**, 2469–2479

(2023).

84. Garcia-Sifuentes, Y. & Maney, D. L. Reporting and misreporting of sex differences in the

biological sciences. *eLife* **10**, e70817 (2021).

85. Bose, B. *et al.* GXwasR: A Toolkit for Investigating Sex-Differentiated Genetic Effects on

Complex Traits. 2025.06.10.25329327 Preprint at

https://doi.org/10.1101/2025.06.10.25329327 (2025).

86. Poelen, E. A. P., Engels, R. C. M. E., Scholte, R. H. J., Boomsma, D. I. & Willemsen, G.

Similarities in drinking behavior of twin's friends: moderation of heritability of alcohol use.

Behav. Genet. **39**, 145–153 (2009).

87. Dick, D. M. *et al.* Gender differences in friends' influences on adolescent drinking: a genetic

epidemiological study. *Alcohol. Clin. Exp. Res.* **31**, 2012–2019 (2007).

88. Miao, J. *et al.* PIGEON: a statistical framework for estimating gene-environment interaction

for polygenic traits. *Nat. Hum. Behav.* **9**, 1654–1668 (2025).

860